RxDoctor Payments Data

Razi Rashid, MD

Neurology · Webster, TXNPI 1962651067

Payments from drug & device makers

$383,675in general payments, 2019–2025

Across 514 payments — averaging $746.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$374K
  • UCB, Inc.$1K
  • AbbVie$1K
  • SK Life Science, Inc.$534
  • Jazz Pharmaceuticals Inc.$471
  • Takeda Pharmaceuticals U.S.A., Inc.$443
  • plus $6K from 54 others

What the payments were for

  • Speaking & faculty fees$220%
  • Food & beverage$10,737100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis42$373,672
UCB, Inc.50$1,372
AbbVie(2 entities)72$1,359
SK Life Science, Inc.24$534
Jazz Pharmaceuticals Inc.19$471
Takeda Pharmaceuticals U.S.A., Inc.18$443
AstraZeneca20$437
Argenx US, Inc.15$379
Grifols USA, LLC21$377
Neurocrine Biosciences, Inc.13$299
Pfizer13$288
Livanova USA, Inc.10$276
Sumitomo Pharma America, Inc.19$273
Catalyst Pharmaceuticals, Inc.12$253
Teva Pharmaceuticals USA, Inc.14$229
Lundbeck LLC9$222
Boston Scientific8$186
W. L. Gore & Associates, Inc.1$182
CSL Behring7$170
Eisai Inc.9$163
Biogen8$162
Genentech USA, Inc.8$160
Sunovion Pharmaceuticals Inc.15$138
Lilly USA, LLC7$120
Amgen6$115
Aquestive Therapeutics, Inc.6$113
ANI Pharmaceuticals, Inc.5$109
Abbott6$106
Johnson & Johnson3$101
Supernus Pharmaceuticals, Inc.4$88
Sanofi4$77
EMD Serono, Inc.4$76
Springworks Therapeutics, Inc.3$64
Assertio Therapeutics, Inc.3$62
Mallinckrodt Hospital Products Inc.2$43
Aucta Pharmaceuticals, Inc.5$42
Biohaven Pharmaceuticals, Inc.2$40
Axsome Therapeutics, Inc.2$40
Otsuka America Pharmaceutical, Inc.2$38
Tanabe Pharma America, Inc.2$30
Amneal Pharmaceuticals LLC2$29
Acadia Pharmaceuticals Inc1$25
Corium, LLC1$24
Medtronic1$23
Acorda Therapeutics, Inc1$22
Immedica Pharma US, Inc.1$22
Scilex Pharmaceuticals Inc.1$20
Biohaven Pharmaceutical Holding Company Ltd.1$19
Upsher-smith Laboratories LLC1$19
Mallinckrodt Enterprises LLC1$18
Xeris Pharmaceuticals, Inc.1$16
Kyowa Kirin, Inc.1$16
Vertical Pharmaceuticals, LLC1$15
Greenwich Biosciences, Inc.1$15
Inspire Medical Systems, Inc.1$15
TG Therapeutics, Inc.1$15
Avion Pharmaceuticals1$15
Strongbridge US Inc.1$14
Arbor Pharmaceuticals, Inc.1$13
IBSA Pharma Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$383,675 in reported general payments places this provider in the 90th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$225,921
Medicare patients
261
Services billed
2,241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate20$185,234
NuplazidPimavanserin Tartrate12$67,692
FycompaPerampanel45$51,124
BotoxOnabotulinumtoxina26$47,364
EpidiolexCannabidiol (Cbd)13$20,529
NuedextaDextromethorphan Hbr/Quinidine12$17,749
XcopriCenobamate15$15,496
NayzilamMidazolam11$12,706
Lacosamide76$5,571
Memantine Hcl160$4,971
Tiagabine Hcl11$3,426
Rasagiline Mesylate12$3,418
Levetiracetam87$3,147
RivastigmineRivastigmine Tartrate37$2,380
Oxcarbazepine50$1,880

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$299$185,23420 claims
Acadia Pharmaceuticals IncNuplazid$25$67,69212 claims
Eisai Inc.Fycompa$163$51,12445 claims
AbbVieBotox$1,359$47,36426 claims
SK Life Science, Inc.Xcopri$534$15,49615 claims
UCB, Inc.Nayzilam$1,372$12,70611 claims
Upsher-smith Laboratories LLCTopiramate$19$43537 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,246 neurology providers in Texas.

Other neurology in Webster

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →